Literature DB >> 23260200

Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1.

Biao Hu1, Zhe Wu, Polla Hergert, Craig A Henke, Peter B Bitterman, Sem H Phan.   

Abstract

Poly(ADP-ribosyl)ation (PARylation) is a post-translational protein modification effected by enzymes belonging to the poly(ADP-ribose) polymerase (PARP) superfamily, mainly by PARP-1. The key acceptors of poly(ADP-ribose) include PARP-1 itself, histones, DNA repair proteins, and transcription factors. Because many of these factors are involved in the regulation of myofibroblast differentiation, we examined the role of PARylation on myofibroblast differentiation. Overexpression of PARP-1 with an expression plasmid activated expression of the α-SMA gene (Acta2), a marker of myofibroblast differentiation in lung fibroblasts. Suppression of PARP-1 activity or gene expression with PARP-1 inhibitors or siRNA, respectively, had the opposite effect on these cells. PARP-1-deficient cells also had reduced α-SMA gene expression. DNA pyrosequencing identified hypermethylated regions of the α-SMA gene in PARP-1-deficient cells, relative to wild-type cells. Interestingly, and of potential relevance to human idiopathic pulmonary fibrosis, PARP activity in lung fibroblasts isolated from idiopathic pulmonary fibrosis patients was significantly higher than that in cells isolated from control subjects. Furthermore, PARP-1-deficient mice exhibited reduced pulmonary fibrosis in response to bleomycin-induced lung injury, relative to wild-type controls. These results suggest that PARylation is important for myofibroblast differentiation and the pathogenesis of pulmonary fibrosis.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23260200      PMCID: PMC3532707          DOI: 10.1016/j.ajpath.2012.09.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

Review 1.  Parabronchial smooth muscle cells and alveolar myofibroblasts in lung development.

Authors:  Namjin Kim; Thiennu H Vu
Journal:  Birth Defects Res C Embryo Today       Date:  2006-03

2.  Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression.

Authors:  Qiong Gan; Tadashi Yoshida; Jian Li; Gary K Owens
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

3.  Biology of fibroblasts and myofibroblasts.

Authors:  Sem H Phan
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

4.  An essential role for CCAAT/enhancer binding protein beta in bleomycin-induced pulmonary fibrosis.

Authors:  B Hu; M R Ullenbruch; H Jin; M Gharaee-Kermani; S H Phan
Journal:  J Pathol       Date:  2007-03       Impact factor: 7.996

5.  Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription.

Authors:  Paul O Hassa; Sandra S Haenni; Christine Buerki; Nadja I Meier; William S Lane; Heather Owen; Monika Gersbach; Ralph Imhof; Michael O Hottiger
Journal:  J Biol Chem       Date:  2005-10-04       Impact factor: 5.157

Review 6.  Poly(ADP-ribose): novel functions for an old molecule.

Authors:  Valérie Schreiber; Françoise Dantzer; Jean-Christophe Ame; Gilbert de Murcia
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

7.  Gut-enriched Krüppel-like factor interaction with Smad3 inhibits myofibroblast differentiation.

Authors:  Biao Hu; Zhe Wu; Tianju Liu; Matthew R Ullenbruch; Hong Jin; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2006-07-20       Impact factor: 6.914

Review 8.  Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

Authors:  Paul O Hassa; Sandra S Haenni; Michael Elser; Michael O Hottiger
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

9.  Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis.

Authors:  Gakuhei Son; Yuji Iimuro; Ekihiro Seki; Tadamichi Hirano; Yasufumi Kaneda; Jiro Fujimoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-07-19       Impact factor: 4.052

Review 10.  The myofibroblast: one function, multiple origins.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Andrea Galli; Marie-Luce Bochaton-Piallat; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more
  19 in total

Review 1.  Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.

Authors:  Ana L Mora; Marta Bueno; Mauricio Rojas
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

2.  Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.

Authors:  Jason D Doles; Kelly A Hogan; Jennifer O'Connor; Andrea E Wahner Hendrickson; Olivia Huston; Aminah Jatoi
Journal:  J Palliat Med       Date:  2018-05-24       Impact factor: 2.947

3.  Reemergence of hedgehog mediates epithelial-mesenchymal crosstalk in pulmonary fibrosis.

Authors:  Biao Hu; Jianhua Liu; Zhe Wu; Tianju Liu; Matthew R Ullenbruch; Lin Ding; Craig A Henke; Peter B Bitterman; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

Review 4.  Beyond the genome: epigenetic mechanisms in lung remodeling.

Authors:  James S Hagood
Journal:  Physiology (Bethesda)       Date:  2014-05

5.  Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling.

Authors:  Guo-Shuai Feng; Cui-Ge Zhu; Zhuo-Ming Li; Pan-Xia Wang; Yi Huang; Min Liu; Ping He; Lan-Lan Lou; Shao-Rui Chen; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2017-02-27       Impact factor: 6.150

6.  Identifying Family-Member-Specific Targets of Mono-ARTDs by Using a Chemical Genetics Approach.

Authors:  Ian Carter-O'Connell; Haihong Jin; Rory K Morgan; Roko Zaja; Larry L David; Ivan Ahel; Michael S Cohen
Journal:  Cell Rep       Date:  2016-01-07       Impact factor: 9.423

7.  In vivo vizualisation of mono-ADP-ribosylation by dPARP16 upon amino-acid starvation.

Authors:  Angelica Aguilera-Gomez; Marinke M van Oorschot; Tineke Veenendaal; Catherine Rabouille
Journal:  Elife       Date:  2016-11-22       Impact factor: 8.140

8.  HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway.

Authors:  Laura Lucarini; Mariaconcetta Durante; Cecilia Lanzi; Alessandro Pini; Giulia Boccalini; Laura Calosi; Flavio Moroni; Emanuela Masini; Guido Mannaioni
Journal:  J Cell Mol Med       Date:  2016-10-04       Impact factor: 5.310

Review 9.  Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

Authors:  Nicola Curtin; Krisztián Bányai; James Thaventhiran; John Le Quesne; Zsuzsanna Helyes; Péter Bai
Journal:  Br J Pharmacol       Date:  2020-07-05       Impact factor: 8.739

10.  Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription.

Authors:  Fabio Ciccarone; Elisabetta Valentini; Maria Giulia Bacalini; Michele Zampieri; Roberta Calabrese; Tiziana Guastafierro; Germano Mariano; Anna Reale; Claudio Franceschi; Paola Caiafa
Journal:  Oncotarget       Date:  2014-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.